Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 82.70B |
| Revenue (ttm) | 44.07B |
| Net Income (ttm) | 5.01B |
| Shares Out | n/a |
| EPS (ttm) | 2.47 |
| PE Ratio | 16.49 |
| Forward PE | 7.87 |
| Dividend | 2.24 (5.58%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 3,310 |
| Average Volume | 2,407 |
| Open | 41.01 |
| Previous Close | 40.93 |
| Day's Range | 40.06 - 41.15 |
| 52-Week Range | 38.67 - 58.79 |
| Beta | 0.39 |
| RSI | 45.04 |
| Earnings Date | Jul 31, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
Applications supported by positive results from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials, in which significantly more patients treated with Sotyktu achieved ACR20 response com...
Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl ® (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with...
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with my...
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 to $346.
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis (apixaban) Option
The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis (apixaban) via our Alliance’s patient resource Eliqu...
Bristol-Myers and Pfizer to offer 40% discount on blockbuster blood thinner Eliquis - report
Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE: BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzing...
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
Bristol-Myers Squibb & Co. (NYSE: BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, a...
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Sign up now: Procurement leaders convene to discuss resilient growth and innovation
Business Insider's July 30 virtual event features executives talking about procurement innovation strategies. The panel features experts from Bristol-Myers Squibb and Amazon Business.
Price Over Earnings Overview: Bristol-Myers Squibb
Looking into the current session, Bristol-Myers Squibb Inc. (NYSE: BMY) shares are trading at $47.05, after a 1.22% drop. Over the past month, the stock decreased by 3.08% , but over the past year, i...
IDEXX, DexCom lead S&P 500 healthcare gains in Q2; UnitedHealth and Bristol Myers Squibb among top laggards
Our bottom 5 stocks for the first half of 2025 and why we still own them
This is what it will take to for a turnaround in shares of Salesforce, Apple, Bristol Myers, DuPont and Danaher.
Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset
Bristol-Myers Squibb: Great Dividend But Questionable Growth Prospects
Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
Bristol-Myers Squibb: Still Challenged, But Some Green Shoots Arrive
Bristol Myers wins favorable FDA label updates for cell therapies Breyanzi and Abecma
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; l...
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts t...
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July. Und...
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug
Cignaaccused BristolMyers Squibb of violating antitrust law by keeping generic versions of its blood cancerdrug Pomalyst off the market to retain a monopoly.